A very interesting article appeared in the Saturday, November 24, 2012 edition of the Washington Post. According to the article The New England Journal of Medicine which is among the most prestigious medical journal in the world regularly features articles over which pharmaceutical companies and their employees exert significant influence. The problem is simple, over [...]
I just cannot remember where I put my keys. What is my home telephone number? What is his name, you know the guy I sit next to everyday in the office? Sound familiar, maybe because you are on hormone deprivation therapy (ADT) to treat your advanced prostate cancer. This can explain why your normally intact [...]
In the prostate cancer world we often discuss treatment options, some approved by the FDA and some not approved. Among the treatment options bantered about are statins (3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor) and nonsteroidal anti-inflammatory drugs (NSAIDs). According to the folklore both these drugs are associated with reducing the risk of prostate cancer and improved [...]
The Early Access Committee on which Malecare sits has been successful in adding an additional site in Long Island, New York to the Early Access Trial of Radium-233 Chloride (Alpharedin) for men with advanced prostate cancer who are castrate resistant and have at least two (2) bone metastases. If you are interested in this trial [...]
Medivation, the pharmaceutical company that owns Xtandi (formerly known as MDV-3100), the new androgen receptor antagonist to treat castrate resistant advanced prostate cancer has a number of active clinical trials, despite the fact that it has already been approved for use. The current FDA approval is specific; it has been approved for men who are [...]